Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, et al.. HSS J. 2025; 21(4):485–495.
PubMed 40756949 · PMC12313605 · doi:10.1177/15563316251355551
Searches for and appraises all the studies on a question. Does not itself test anything.
- Who or what was studied
- 36 studies: 35 preclinical (animal) and 1 clinical, from 1993 to June 2024
- Design
- Systematic review (PubMed, Cochrane, Embase)
What it found
Nearly all the evidence on BPC-157 is from animals. Those studies suggest faster healing of muscle, tendon, ligament and bone injuries. The one clinical report was a retrospective study of knee injections in which 7 of 12 patients reported relief lasting more than 6 months. No clinical safety data were found.
What it doesn't show
Everything reviewed was low-level evidence (level IV and V: case series, expert opinion and preclinical work), so the review cannot show that BPC-157 works in people. The authors warn that adverse effects are possible because of unregulated manufacturing, contamination and unknown clinical safety.
Funding and conflicts of interest
Some authors disclose relationships with orthopaedic device companies (Stryker, Smith & Nephew, Arthrex, Mitek). The other authors declare none.
Summary written from the study's abstract and checked against PubMed on November 9, 2026. How we check studies. Educational information, not medical advice.
Related studies
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine (Tewari et al., 2026)
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Mendias et al., 2026)
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (McGuire et al., 2025)
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study (Lee et al., 2025)